New scan could spot hidden prostate cancer

NCT ID NCT07600554

Recruiting now Diagnosis Sponsor: Philogen S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to see if it is safe and can help detect cancer that has spread or come back. Participants receive one injection and then undergo PET scans to measure radiation doses and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-OncoACP3 (a radioactive imaging agent)
What this could lead to: If successful, this could provide a new way to detect prostate cancer spread or recurrence using PET scans, potentially guiding treatment decisions.
What could go wrong: This is a very early phase 1 study with only 20 participants, focused on safety and dosing, not on effectiveness. The imaging agent may not work as hoped or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
RECRUITING

Bergamo, Bergamo, 24127, Italy
Ospedale San Raffaele S.r.l.
RECRUITING

Milan, Milano, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.